Stryker Corporation is a leading medical technology company that specializes in designing, manufacturing, and marketing innovative products and services for healthcare professionals and patients. The company offers a diverse range of medical devices, including surgical equipment, orthopedic implants, neurotechnology, and surgery assistance products. Stryker focuses on advancing healthcare through cutting-edge technology and solutions that enhance patient care, improve surgical outcomes, and streamline hospital operations. With a commitment to innovation and quality, Stryker plays a pivotal role in the medical industry, helping healthcare providers deliver effective treatment and improve the quality of life for patients around the world. Read More
Medical technology company Stryker (NYSE:SYK) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.4% year on year to $6.59 billion. Its non-...
Medical technology company Stryker (NYSE:SYK) will be reporting earnings this Thursday afternoon. Here’s what investors should know. Stryker missed analysts’...
Stryker (NYSE:SYK) has outperformed the market over the past 20 years by 1.04% on an annualized basis producing an average annual return of 10.3%. Currently, Stryker has a market capitalization of $122.02 billion.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Portage, Michigan, July 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) will host a webcast at 4:30 p.m. (Eastern time) on Thursday, July 30, 2026, to discuss its second quarter 2026 financial results. The live webcast can be accessed at Stryker - Events & Presentations. An archive of the webcast will also be available at Stryker’s website beginning approximately two hours after the live call ends.
Stryker (NYSE:SYK) has outperformed the market over the past 20 years by 1.17% on an annualized basis producing an average annual return of 10.45%. Currently, Stryker has a market capitalization of $120.58 billion.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Over the last six months, Stryker’s shares have sunk to $310.00, producing a disappointing 11.9% loss - a stark contrast to the S&P 500’s 9.3% gain. This was...
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...
BioStar Capital, a venture capital firm focused on transformative medical technologies, has announced a landmark pre-FDA exit of Amplitude Vascular Systems, Inc. (AVS), a medical technology company that created a next-generation hydraulic intravascular lithotripsy (IVL) platform to treat calcified peripheral arterial disease. Upon acquiring AVS for up to $835 million, Stryker (NYSE:SYK), a global leader in medical technologies, called the deal a milestone in the expansion of its peripheral vascular portfolio.
